Galectin Historical Financial Ratios
| GALT Stock | USD 1.15 0.28 32.18% |
Galectin Therapeutics is recently reporting on over 105 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 0.0 or Invested Capital of 0.0 will help investors to properly organize and evaluate Galectin Therapeutics financial condition quickly.
Galectin |
About Galectin Financial Ratios Analysis
Galectin TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Galectin Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Galectin financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Galectin Therapeutics history.
Galectin Therapeutics Financial Ratios Chart
Add Fundamental
Dividend Yield
Dividend Yield is Galectin Therapeutics dividend as a percentage of Galectin Therapeutics stock price. Galectin Therapeutics dividend yield is a measure of Galectin Therapeutics stock productivity, which can be interpreted as interest rate earned on an Galectin Therapeutics investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Payables Turnover
A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.Most ratios from Galectin Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Galectin Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Galectin Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Galectin Stock please use our How to Invest in Galectin Therapeutics guide.At this time, Galectin Therapeutics' Capex To Depreciation is comparatively stable compared to the past year. Cash Per Share is likely to gain to 0.78 in 2024, despite the fact that Book Value Per Share is likely to grow to (0.95).
Galectin Therapeutics fundamentals Correlations
Click cells to compare fundamentals
Galectin Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Galectin Therapeutics fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Dividend Yield | 0.002637 | 0.001072 | 0.001411 | 0.001445 | 0.001662 | 0.001579 | |
| Ptb Ratio | 3.28 | 4.32 | 135.67 | (1.98) | (1.66) | (1.57) | |
| Book Value Per Share | 0.87 | 0.42 | 0.0153 | (0.57) | (1.0) | (0.95) | |
| Operating Cash Flow Per Share | (0.21) | (0.36) | (0.42) | (0.52) | (0.55) | (0.58) | |
| Pb Ratio | 3.28 | 4.32 | 135.67 | (1.98) | (1.66) | (1.57) | |
| Free Cash Flow Per Share | (0.21) | (0.36) | (0.42) | (0.52) | (0.55) | (0.58) | |
| Roic | (0.3) | (0.79) | (1.02) | (6.56) | (3.31) | (3.48) | |
| Net Income Per Share | (0.35) | (0.26) | (0.41) | (0.53) | (0.66) | (0.68) | |
| Cash Per Share | 0.91 | 0.48 | 0.68 | 0.31 | 0.43 | 0.78 | |
| Pocfratio | (13.77) | (6.2) | (4.98) | (2.16) | (3.03) | (3.18) | |
| Interest Coverage | (154.46) | (269.47) | (61.72) | (37.13) | (14.86) | (15.6) | |
| Payout Ratio | (0.0294) | (0.005826) | (0.005521) | (0.002474) | (0.002227) | (0.002338) | |
| Pfcf Ratio | (13.77) | (6.2) | (4.98) | (2.16) | (3.03) | (3.18) | |
| Income Quality | 0.98 | 0.73 | 0.82 | 0.88 | 0.8 | 0.9 | |
| Roe | (0.29) | (0.79) | (34.69) | 1.16 | 0.68 | 0.65 | |
| Ev To Operating Cash Flow | (9.4) | (4.89) | (4.55) | (2.85) | (4.43) | (4.65) | |
| Pe Ratio | (11.17) | (5.43) | (3.91) | (1.71) | (2.43) | (2.55) | |
| Return On Tangible Assets | (0.28) | (0.79) | (0.74) | (1.84) | (1.46) | (1.53) | |
| Ev To Free Cash Flow | (9.4) | (4.89) | (4.55) | (2.85) | (4.43) | (4.65) | |
| Earnings Yield | (0.0896) | (0.18) | (0.26) | (0.58) | (0.41) | (0.43) | |
| Net Debt To E B I T D A | 3.6 | 1.16 | 0.35 | (0.56) | (228.45) | (217.03) | |
| Current Ratio | 17.1 | 5.46 | 4.63 | 1.58 | 1.77 | 1.68 | |
| Tangible Book Value Per Share | 0.87 | 0.42 | 0.0153 | (0.57) | (1.0) | (0.95) | |
| Graham Number | 2.24 | 2.19 | 0.43 | 2.91 | 3.92 | 3.37 | |
| Graham Net Net | 0.85 | 0.38 | (0.022) | (0.62) | (1.04) | (0.99) | |
| Interest Debt Per Share | 0.001665 | 0.001526 | 0.5 | 0.69 | 1.24 | 1.3 | |
| Enterprise Value Over E B I T D A | (7.74) | (4.31) | (3.69) | (2.34) | (722.83) | (686.69) | |
| Price Earnings Ratio | (11.17) | (5.43) | (3.91) | (1.71) | (2.43) | (2.55) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Galectin Stock Analysis
When running Galectin Therapeutics' price analysis, check to measure Galectin Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galectin Therapeutics is operating at the current time. Most of Galectin Therapeutics' value examination focuses on studying past and present price action to predict the probability of Galectin Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galectin Therapeutics' price. Additionally, you may evaluate how the addition of Galectin Therapeutics to your portfolios can decrease your overall portfolio volatility.